The notices it replaced
- Reissues: PAR-14-270 Innovative Therapies and Tools for Screenable Disorders in Newborns (R01)
- 2 steps back: PAR-10-230 Innovative Therapies and Tools for Screenable Disorders in Newborns (R01)
- 3 steps back: PAR-07-184 Innovative Therapies and Clinical Studies for Screenable Disorders (R01)
- 4 steps back: PAR-06-060
Replaced by PAR-21-353.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,667,798 in first-year total cost, median $399,649.
Most frequent study sections
- Therapeutic Approaches to Genetic Diseases Study Section[TAG]6
- Special Emphasis Panel[ZRG1 GGG-Q (50)]4
- Special Emphasis Panel[ZRG1 GGG-A (50)]2
- Special Emphasis Panel[ZRG1 GGG-B (50)]1
- Special Emphasis Panel[ZRG1 GGG-K (51)]1
Most frequent institutions
- BOSTON CHILDREN'S HOSPITAL2
- OREGON HEALTH & SCIENCE UNIVERSITY2
- RESEARCH INST OF FOX CHASE CAN CTR2
- ALBERT EINSTEIN COLLEGE OF MEDICINE1
- MAYO CLINIC ROCHESTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Enhancement of Newborn Screening Diagnostic Paradigms to Improve the Efficacy of Treatment for Krabbe Disease, Pompe Disease, and Mucopolysaccharidosis Type 11R01HD104814-01A1 | LANGAN, THOMAS J | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $760,644 | TAG |
| 2021 | Non-invasive functional assessment and pathogenesis of Morquio A1R01HD102545-01A1 | TOMATSU, SHUNJI | NEMOURS CHILDREN'S HOSPITAL, DELAWARE, DE | $593,522 | TAG |
| 2021 | Optimizing medium-chain lipids for the treatment of long-chain fatty acid oxidation disorders1R01HD103602-01 | GOETZMAN, ERIC S | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $333,705 | TAG |
| 2020 | Multiplex gene sequencing and metabolomics analysis from newborn dried blood spots to improve screening and diagnosis of metabolic disorders.1R01HD102537-01 | SCHARFE, CURT | YALE UNIVERSITY, CT | $542,483 | TAG |
| 2019 | NY ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program2R01HD073292-06A1 | WASSERSTEIN, MELISSA PITTEL | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $686,197 | TAG |
| 2019 | Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency1R01NS110596-01 | LIPSHUTZ, GERALD S | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $341,250 | TAG |
| 2017 | Diet and the CPT1A arctic variant: Impact on the Health of Alaska Native Children1R01HD089951-01 · under PAR-14-270 | DILLARD, DENISE AKOELLER, DAVID M | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $437,407 | ZRG1 |
| 2017 | Towards Improved Therapy for Classic Galactosemia1R01HD089933-01A1 · under PAR-14-270 | LAI, KENT | UNIVERSITY OF UTAH, UT | $314,708 | ZRG1 |
| 2016 | Novel therapy for monoamine neurotransmitter deficiency in PKU2R01NS080866-05 · under PAR-14-270 | HARDING, CARY O. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $397,279 | ZRG1 |
| 2016 | A New View of PAH Allostery - Correlation with Disease-Associated Alleles1R01NS100081-01A1 · under PAR-14-270 | JAFFE, EILEEN K | RESEARCH INST OF FOX CHASE CAN CTR, PA | $382,611 | ZRG1 |
| 2015 | Immunodeficient FAH-/- Pigs1R01DK106667-01 · under PAR-14-270 | NYBERG, SCOTT L | MAYO CLINIC ROCHESTER, MN | $402,019 | ZRG1 |
| 2014 | Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia1R01HD076258-01A1 · under PAR-10-230 | GRANT, PATRICIA ELLEN | BOSTON CHILDREN'S HOSPITAL, MA | $714,129 | ZRG1 |
| 2014 | Treatment of CBS Deficiency with Proteostasis Modulators1R01DK101404-01 · under PAR-10-230 | KRUGER, WARREN D | RESEARCH INST OF FOX CHASE CAN CTR, PA | $397,163 | ZRG1 |
| 2014 | Genetic screening and therapies for nemaline myopathies1R01HD075802-01A1 · under PAR-10-230 | BEGGS, ALAN H. | BOSTON CHILDREN'S HOSPITAL, MA | $364,681 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.